A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Trial Identifier: TED15297
Sponsor: Sanofi
Collaborator:
Biontech RNA Pharmaceuticals GmbH
Start Date: January 2019
Primary Completion Date: July 2022
Study Completion Date: February 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BELGIUM BRUSSELS, BELGIUM, 1200
BELGIUM GENT, BELGIUM, 9000
BELGIUM LEUVEN, BELGIUM, 3000
FRANCE MARSEILLE, FRANCE, 13885
FRANCE PARIS, FRANCE, 75010
FRANCE VILLEJUIF, FRANCE, 94805
GERMANY HAMBURG, GERMANY, 20246
GERMANY HEIDELBERG, GERMANY, 69120
GERMANY MAINZ, GERMANY, 55131
GERMANY MANNHEIM, GERMANY, 68167
GERMANY TÜBINGEN, GERMANY, 72076
NETHERLANDS NIJMEGEN, NETHERLANDS, 6525 GA
NETHERLANDS ROTTERDAM, NETHERLANDS, 3015 CE
SPAIN, Catalunya [Cataluña] BARCELONA, Catalunya [Cataluña], SPAIN, 08036
SPAIN, Navarra PAMPLONA, Navarra, SPAIN, 31008
SPAIN, Valencia VALENCIA, Valencia, SPAIN, 46014
UNITED STATES, Massachusetts BOSTON, Massachusetts, UNITED STATES, 02215
UNITED STATES, Ohio CLEVELAND, Ohio, UNITED STATES, 44195
UNITED STATES, Texas HOUSTON, Texas, UNITED STATES, 77030